Skip to main content

Advertisement

Table 2 First and second-line targeted drugs used in the present cohort

From: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

First targeted therapy Second targeted therapy
Everolimus (n = 520) Sorafenib (n = 240) Sunitinib (n = 228) Axitinib (n = 29) Pazopanib (n = 10) Temsirolimus (n = 1) Bevacizumab + IFN (n = 1)
Bevacizumab + IFN 5 (1.0%) 4 (1.7%) 19 (8.3%) 0 (0.0%) 7 (70.0%) 0 (0.0%) 0 (0.0%)
Sorafenib 93 (17.9%) 0 (0.0%) 139 (61.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Sunitinib 390 (75.0%) 232 (96.7%) 0 (0.0%) 28 (96.6%) 3 (30.0%) 1 (100.0%) 1 (100.0%)
Temsirolimus 0 (0.0%) 2 (0.8%) 21 (9.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pazopanib 32 (6.2%) 2 (0.8%) 49 (21.5%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
  1. IFN interferon-α